Sodium glucose co-transporter 2 inhibitor treatment improved glycemic control and reduced liver fat mass in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus.

Body weight reduction was mostly due to a reduction in fat mass, especially visceral fat, rather than skeletal muscle mass.

Sodium glucose co-transporter 2 inhibitors may be highly useful therapeutic agents for patients with nonalcoholic fatty liver disease and type 2 diabetes.